|
|
Article: Rash often seen with new class of cancer drugs.(Dermatology)
- Article from:
- Internal Medicine News
- Article date:
- March 1, 2005
- Author:
CopyrightCOPYRIGHT 2005 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
One of the hottest new treatment advances in oncology has spawned an unwelcome dermatologic side effect.
Signal transduction inhibitors, a new class of cancer drugs targeting solid tumors without the toxic side effects of chemotherapy, are causing treatment-resistant folliculitis in up to 75% of patients.
"We've been trying, but we haven't hit on a successful treatment yet," said Peter Heald, M.D., professor of dermatology at Yale University, New Haven. "They get better, but if you are talking about clearing--never.
"And we are talking about long courses of treatment with these [cancer] drugs," he added.
Signal transduction ...